Swiss National Bank
NAGE

Swiss National Bank’s Niagen Bioscience NAGE Stock Holding History

Swiss National Bank’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-110,100
Closed -$700K – 2355
2025
Q4 		$700K Buy
110,100
+3,200
+3% +$22.3K ﹤0.01% 2253
2025
Q3 		$997K Buy
+106,900
New +$1.08M ﹤0.01% 2167

Other funds holding NAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Swiss National Bank's NAGE Position: Q1 2026 in Review

Swiss National Bank sold out of Niagen Bioscience (NAGE) in Q1 2026, closing a stake of 110,100 shares — an estimated $700K sold.

Swiss National Bank first reported a position in NAGE in Q3 2025 and held it in 2 quarters. The position peaked at $997K in Q3 2025. 143 funds tracked by Wall St. Rank hold NAGE as of Q1 2026.

  • Swiss National Bank reported no remaining Niagen Bioscience position as of Q1 2026 after selling out during the quarter.
  • Swiss National Bank sold 110,100 Niagen Bioscience shares in Q1 2026, an estimated $700K.
  • Swiss National Bank first reported a position in Niagen Bioscience in Q3 2025 and held it in 2 quarters.
  • Swiss National Bank's Niagen Bioscience position peaked at $997K in Q3 2025.
  • 143 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2026.

Based on Swiss National Bank's 13F filing for Q1 2026, filed 7 May 2026.